Patents by Inventor ERNEST BOGNAR

ERNEST BOGNAR has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS FOR THE TREATMENT OF LUNG TUMORS
    Publication number: 20230338284
    Abstract: The present disclosure provides composition formulated into inhalable dosage forms for treating a tumor or cancer in the lung. The compositions can be lyophilized compositions formulated for pulmonary delivery via a device.
    Type: Application
    Filed: February 27, 2023
    Publication date: October 26, 2023
    Applicant: GRADALIS, INC.
    Inventors: DAVID SHANAHAN, John Nemunaitis, Ernest Bognar
  • METHODS FOR THE TREATMENT OF VIRAL RESPIRATORY INFECTIONS
    Publication number: 20230144927
    Abstract: Compositions and methods for treatment of a respiratory infection by a virus are disclosed herein. In some embodiments, the composition comprises pulmonary administration of a plasmid encoding a GM-CSF sequence and a bifunctional shRNA capable of inhibiting furin expression. In some embodiments, the virus is SARS-CoV-2.
    Type: Application
    Filed: October 31, 2022
    Publication date: May 11, 2023
    Applicant: GRADALIS, INC.
    Inventors: DAVID SHANAHAN, JOHN NEMUNAITIS, ERNEST BOGNAR
  • Methods for treating cancers
    Patent number: 11400170
    Abstract: Compositions and methods for prevention of ovarian cancer recurrence and for the treatment of BRCA1/2-wild type ovarian cancer are disclosed herein. In some embodiments, the composition comprises an autologous tumor cell vaccine comprising cells genetically modified for furin knockdown and GM-CSF expression. In some embodiments, the method comprises administration of an autologous tumor cell vaccine prior to administration of a combination of the autologous tumor cell vaccine and atezolizumab. Also disclosed herein are methods for treating a cancer in an individual comprising a wild-type BRCA1 gene, a wild-type BRCA2 gene, or a combination thereof, and is identified as homologous recombination deficiency (HRD)-negative.
    Type: Grant
    Filed: January 25, 2021
    Date of Patent: August 2, 2022
    Assignee: GRADALIS, INC.
    Inventors: John Nemunaitis, Ernest Bognar
  • METHODS FOR TREATING CANCERS
    Publication number: 20210220488
    Abstract: Compositions and methods for prevention of ovarian cancer recurrence and for the treatment of BRCA1/2-wild type ovarian cancer are disclosed herein. In some embodiments, the composition comprises an autologous tumor cell vaccine comprising cells genetically modified for furin knockdown and GM-CSF expression. In some embodiments, the method comprises administration of an autologous tumor cell vaccine prior to administration of a combination of the autologous tumor cell vaccine and atezolizumab. Also disclosed herein are methods for treating a cancer in an individual comprising a wild-type BRCA1 gene, a wild-type BRCA2 gene, or a combination thereof, and is identified as homologous recombination deficiency (HRD)-negative.
    Type: Application
    Filed: January 25, 2021
    Publication date: July 22, 2021
    Applicant: GRADALIS, INC.
    Inventors: JOHN NEMUNAITIS, ERNEST BOGNAR